JP2013027385A5 - - Google Patents

Download PDF

Info

Publication number
JP2013027385A5
JP2013027385A5 JP2012021972A JP2012021972A JP2013027385A5 JP 2013027385 A5 JP2013027385 A5 JP 2013027385A5 JP 2012021972 A JP2012021972 A JP 2012021972A JP 2012021972 A JP2012021972 A JP 2012021972A JP 2013027385 A5 JP2013027385 A5 JP 2013027385A5
Authority
JP
Japan
Prior art keywords
cells
blood
cell population
amplifying
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012021972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013027385A (ja
JP5572863B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from JP2012021972A external-priority patent/JP5572863B2/ja
Priority to JP2012021972A priority Critical patent/JP5572863B2/ja
Priority to CN201280031188.5A priority patent/CN103620022B/zh
Priority to MYPI2013004630A priority patent/MY161389A/en
Priority to KR1020147001579A priority patent/KR101963920B1/ko
Priority to AU2012274478A priority patent/AU2012274478B2/en
Priority to EP12801859.5A priority patent/EP2725100B1/en
Priority to HK14103574.2A priority patent/HK1190432B/xx
Priority to US14/129,143 priority patent/US9404083B2/en
Priority to PCT/JP2012/065718 priority patent/WO2012176796A1/ja
Priority to CA2840161A priority patent/CA2840161C/en
Publication of JP2013027385A publication Critical patent/JP2013027385A/ja
Publication of JP2013027385A5 publication Critical patent/JP2013027385A5/ja
Publication of JP5572863B2 publication Critical patent/JP5572863B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012021972A 2011-06-24 2012-02-03 Nk細胞の増幅方法 Active JP5572863B2 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2012021972A JP5572863B2 (ja) 2011-06-24 2012-02-03 Nk細胞の増幅方法
HK14103574.2A HK1190432B (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
PCT/JP2012/065718 WO2012176796A1 (ja) 2011-06-24 2012-06-20 Nk細胞の増幅方法
KR1020147001579A KR101963920B1 (ko) 2011-06-24 2012-06-20 Nk 세포의 증폭 방법
AU2012274478A AU2012274478B2 (en) 2011-06-24 2012-06-20 Method for amplifying NK cells
EP12801859.5A EP2725100B1 (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
CN201280031188.5A CN103620022B (zh) 2011-06-24 2012-06-20 Nk细胞的扩增方法
US14/129,143 US9404083B2 (en) 2011-06-24 2012-06-20 Method for amplifying NK cells
MYPI2013004630A MY161389A (en) 2011-06-24 2012-06-20 Method for amplifying nk cells
CA2840161A CA2840161C (en) 2011-06-24 2012-06-20 Method for amplifying nk cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011140725 2011-06-24
JP2011140725 2011-06-24
JP2012021972A JP5572863B2 (ja) 2011-06-24 2012-02-03 Nk細胞の増幅方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014011951A Division JP5989016B2 (ja) 2011-06-24 2014-01-27 Nk細胞の増幅方法

Publications (3)

Publication Number Publication Date
JP2013027385A JP2013027385A (ja) 2013-02-07
JP2013027385A5 true JP2013027385A5 (https=) 2013-12-12
JP5572863B2 JP5572863B2 (ja) 2014-08-20

Family

ID=47422628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012021972A Active JP5572863B2 (ja) 2011-06-24 2012-02-03 Nk細胞の増幅方法

Country Status (9)

Country Link
US (1) US9404083B2 (https=)
EP (1) EP2725100B1 (https=)
JP (1) JP5572863B2 (https=)
KR (1) KR101963920B1 (https=)
CN (1) CN103620022B (https=)
AU (1) AU2012274478B2 (https=)
CA (1) CA2840161C (https=)
MY (1) MY161389A (https=)
WO (1) WO2012176796A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Nk細胞の調製方法
JP6164650B2 (ja) * 2014-01-20 2017-07-19 国立大学法人九州大学 Nk細胞の調製方法
JP6775426B2 (ja) * 2014-03-07 2020-10-28 エメルセル エスエーエス 臍帯血由来のプールnk細胞並びにがん及び慢性感染症の治療のためのこれらの用途
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
US12398371B2 (en) 2015-01-27 2025-08-26 Korea Research Institute Of Bioscience Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
CN106222141B (zh) * 2016-10-17 2018-10-19 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満 吉和 高活性nk細胞、およびその利用
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
WO2019152663A1 (en) * 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102765799B1 (ko) * 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
JP6543375B1 (ja) * 2018-03-27 2019-07-10 株式会社ガイアバイオメディシン ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用
CN110628714B (zh) * 2018-06-21 2023-03-28 精准生技股份有限公司 用于体外扩增自然杀手细胞及自然杀手t细胞的无血清细胞培养液
CN109161527A (zh) * 2018-09-25 2019-01-08 深圳市五零生命科技有限公司 一种高效的nk细胞扩增方法
MY199770A (en) 2018-11-14 2023-11-22 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
WO2020152661A1 (ja) 2019-01-21 2020-07-30 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
JP6838750B2 (ja) * 2019-01-21 2021-03-03 株式会社ガイアバイオメディシン Nk細胞を含む細胞集団の製造方法
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
JP6697611B2 (ja) * 2019-05-20 2020-05-20 米満 吉和 高活性nk細胞、およびその利用
CN111154721B (zh) * 2020-01-14 2023-10-17 深圳格泰赛尔生物科技有限公司 Nk细胞扩增方法
JP2023519083A (ja) * 2020-01-19 2023-05-10 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 細胞がん治療の強化の為のt細胞死関連遺伝子8(tdag8)調節
US12486492B2 (en) 2020-03-05 2025-12-02 Korea Research Institute Of Bioscience Method for producing memory-like NK cells with ability to express higher levels of NCRs, cytotoxicity, and IFN-γ than NK cells in human peripheral blood
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
AU2024298429A1 (en) * 2023-07-21 2026-01-29 Gaia Biomedicine Inc. Method for producing cell population

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
WO2004056392A1 (en) * 2002-12-23 2004-07-08 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
WO2007103901A2 (en) * 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
JP4275680B2 (ja) 2006-04-28 2009-06-10 裕 照沼 リンパ球の活性・増殖に係る培養方法
JP2007297292A (ja) 2006-04-28 2007-11-15 Kyorin Pharmaceut Co Ltd 1−アルコキシイソキノリン誘導体又はその水和物の製造方法
RU2009110156A (ru) 2006-08-23 2010-09-27 Байнекс Ко., Лтд. (Kr) Способ производства активированных лимфоцитов для иммунотерапии
US8771726B2 (en) 2006-08-28 2014-07-08 Hisamitsu Pharmaceutical Co., Inc Nail patch
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Nk細胞の培養方法及びnk細胞の利用
RU2536242C2 (ru) * 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
US8877182B2 (en) * 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
US9062287B2 (en) * 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
US20130011376A1 (en) 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
JP2011239701A (ja) 2010-05-14 2011-12-01 Tella Inc 樹状細胞の培養方法
KR101039843B1 (ko) 2010-08-30 2011-06-09 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법
JP5840876B2 (ja) 2011-06-24 2016-01-06 テラ株式会社 Nk細胞を増幅するための組成物及び方法

Similar Documents

Publication Publication Date Title
JP2013027385A5 (https=)
AU2012274478A8 (en) Method for amplifying NK cells
Rota et al. Stem cell therapies in kidney diseases: progress and challenges
Lee et al. iPSC-derived MSCs are a distinct entity of MSCs with higher therapeutic potential than their donor-matched parental MSCs
Araujo et al. Comparison of human mesenchymal stromal cells from four neonatal tissues: amniotic membrane, chorionic membrane, placental decidua and umbilical cord
US20210121452A1 (en) Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
Wada et al. Immunomodulatory properties of human periodontal ligament stem cells
US8263065B2 (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
Greiner et al. Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients
CY1123343T1 (el) Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων
JP2016509840A5 (https=)
Torres Crigna et al. Human adipose tissue-derived stromal cells suppress human, but not murine lymphocyte proliferation, via indoleamine 2, 3-dioxygenase activity
Fattizzo et al. Mesenchymal stem cells in aplastic anemia and myelodysplastic syndromes: the “seed and soil” crosstalk
Montesinos et al. Human bone marrow mesenchymal stem/stromal cells exposed to an inflammatory environment increase the expression of ICAM‐1 and release microvesicles enriched in this adhesive molecule: analysis of the participation of TNF‐α and IFN‐γ
AU2022203581A1 (en) Natural killer cells from placenta
JP2016501013A5 (https=)
JP2013537187A5 (https=)
Seo et al. Strategies to potentiate paracrine therapeutic efficacy of mesenchymal stem cells in inflammatory diseases
Markouli et al. Recent advances in adult post-transplant lymphoproliferative disorder
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
Urbinati et al. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease
FI3325612T3 (fi) Menetelmiä ja kompositioita kantasolutransplantaatiota varten
MX387420B (es) Producción de virus en cultivos celulares.
US12023357B2 (en) Rejuvenated aged hematopoietic stem cells and methods of use
Jiang et al. Immune cells and RBCs derived from human induced pluripotent stem cells: method, progress, prospective challenges